《大行報告》花旗:贛鋒鋰業(01772.HK)被市場低估 重申「買入」評級
花旗發表報告指,贛鋒鋰業(01772.HK)今年首季按中國會計準則的純利爲35.25億元人民幣,按年增長640%,按季亦增24%,佔該行及市場今年全年預測分別25%及36%。
該行預期,贛鋒鋰業將受惠於阿根廷「Cauchari」項目於今年下半年開始生產,及鋰化合物價格高企,重申對集團股份「買入」評級,目標價161.6元。
花旗認爲,贛鋒鋰業H股估值相當於今年預測市盈率7倍,及市賬率3倍,相信其股價表現疲弱,主要由於市場憂慮在原材料成本增加下,新能源車的需求問題。不過,該行估計中國的電池生產今年6月會開始提升,令碳酸鋰需求恢復,因此相信贛鋒鋰業估值是被低估。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.